PH12020550462A1 - Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same - Google Patents

Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Info

Publication number
PH12020550462A1
PH12020550462A1 PH12020550462A PH12020550462A PH12020550462A1 PH 12020550462 A1 PH12020550462 A1 PH 12020550462A1 PH 12020550462 A PH12020550462 A PH 12020550462A PH 12020550462 A PH12020550462 A PH 12020550462A PH 12020550462 A1 PH12020550462 A1 PH 12020550462A1
Authority
PH
Philippines
Prior art keywords
methods
pharmaceutical compositions
cocrystals
treatment involving
involving same
Prior art date
Application number
PH12020550462A
Other languages
English (en)
Inventor
Benjamin S Lane
Chong-Hui Gu
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of PH12020550462A1 publication Critical patent/PH12020550462A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/145Maleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235Saturated compounds containing more than one carboxyl group
    • C07C59/245Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265Citric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PH12020550462A 2017-11-02 2020-04-22 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same PH12020550462A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580501P 2017-11-02 2017-11-02
PCT/US2018/058930 WO2019090059A1 (en) 2017-11-02 2018-11-02 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Publications (1)

Publication Number Publication Date
PH12020550462A1 true PH12020550462A1 (en) 2021-03-22

Family

ID=64572453

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020550462A PH12020550462A1 (en) 2017-11-02 2020-04-22 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Country Status (17)

Country Link
US (3) US11345677B2 (enExample)
EP (1) EP3704101A1 (enExample)
JP (3) JP7335877B2 (enExample)
KR (2) KR20240166601A (enExample)
CN (2) CN118359585A (enExample)
AU (2) AU2018360827B2 (enExample)
BR (1) BR112020008598A2 (enExample)
CA (1) CA3081535A1 (enExample)
EA (1) EA202091112A1 (enExample)
IL (2) IL274123B2 (enExample)
MA (1) MA50526A (enExample)
MX (2) MX2020004513A (enExample)
PH (1) PH12020550462A1 (enExample)
SG (1) SG11202003612VA (enExample)
TW (2) TWI839131B (enExample)
UA (1) UA127380C2 (enExample)
WO (1) WO2019090059A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200085832A1 (en) * 2019-11-22 2020-03-19 Agios Pharmaceuticals, Inc. Deuterated analogs of an organic compound
TW202227446A (zh) 2020-08-12 2022-07-16 美商施維雅製藥有限公司 有機化合物之固態形式
WO2023192565A1 (en) 2022-03-31 2023-10-05 Servier Pharmaceuticals Llc Methods of treating enhancing brain tumors using combination therapy
AR133332A1 (es) 2023-07-25 2025-09-17 Servier Lab Sales, cocristales, composiciones farmacéuticas de los mismos, y métodos de tratamiento que implican los mismos
WO2025060940A1 (zh) * 2023-09-18 2025-03-27 贝达药业股份有限公司 突变型idh抑制剂化合物及其盐的固体形式
EP4538262A1 (en) 2023-10-12 2025-04-16 Sandoz Ag Cocrystals of vorasidenib
WO2025168757A1 (en) 2024-02-09 2025-08-14 Les Laboratoires Servier Process for the preparation of vorasidenib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815858C (en) * 2010-11-01 2018-10-16 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
AU2018360827A1 (en) 2020-05-14
IL274123B2 (en) 2024-01-01
SG11202003612VA (en) 2020-05-28
US20210198234A1 (en) 2021-07-01
TWI839131B (zh) 2024-04-11
KR102731624B1 (ko) 2024-11-19
CN111527076B (zh) 2024-03-12
MX2022014792A (es) 2023-01-16
EP3704101A1 (en) 2020-09-09
JP2021501766A (ja) 2021-01-21
EA202091112A1 (ru) 2020-07-23
WO2019090059A1 (en) 2019-05-09
US20220363661A1 (en) 2022-11-17
BR112020008598A2 (pt) 2021-01-26
AU2018360827B2 (en) 2024-02-22
TW201930285A (zh) 2019-08-01
US20240343705A1 (en) 2024-10-17
JP7780576B2 (ja) 2025-12-04
AU2024203186A1 (en) 2024-05-30
TWI796377B (zh) 2023-03-21
JP7499377B2 (ja) 2024-06-13
CA3081535A1 (en) 2019-05-09
JP7335877B2 (ja) 2023-08-30
IL305426B1 (en) 2024-06-01
IL274123B1 (en) 2023-09-01
JP2024113028A (ja) 2024-08-21
CN118359585A (zh) 2024-07-19
IL305426A (en) 2023-10-01
US11851417B2 (en) 2023-12-26
CN111527076A (zh) 2020-08-11
IL274123A (en) 2020-06-30
MA50526A (fr) 2020-09-09
JP2023093666A (ja) 2023-07-04
US11345677B2 (en) 2022-05-31
KR20240166601A (ko) 2024-11-26
IL305426B2 (en) 2024-10-01
KR20200095480A (ko) 2020-08-10
MX2020004513A (es) 2020-09-17
UA127380C2 (uk) 2023-08-02
TW202337885A (zh) 2023-10-01

Similar Documents

Publication Publication Date Title
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MY188139A (en) Sodium channel modulators for the treatment of pain
PH12016502354A1 (en) Pharmaceutical composition
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
WO2016133903A3 (en) Combination therapy for cancer treatment
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MY186134A (en) Curcumin-peptide conjugates and formulations thereof
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
AU2017260751A1 (en) Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine
MX2015016893A (es) Combinacion de ro5503781 y capecitabina para la terapia para el cancer.
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.